Little could be done for children with Dushin muscular dystrophy until the gene

responsible for the disease was known. Hear about the possibilities geneticists are now exploring on the latest episode of

targeting the toughest diseases, a new podcast by Bloomberg Media Studios and Vertex Pharmaceuticals. With Bloomberg, you get the story behind the story, the story behind the

story behind the global birth rate, behind your EV battery's environmental impact, behind

sand, yeah, sand, you get context. And context changes everything. Go to Bloomberg

com to get context. Welcome to the Bloomberg surveillance podcast. I'm Tom Keene.

Daily, we bring you insight from the best in economics, finance, investment, and

international relations.

Find Bloomberg Surveillance on Apple Podcasts, SoundCloud,

Bloomberg.com, and of course, on the Bloomberg.

You know, we've got a guest here that he's done forensic accounting on all these

unicorns we can bring in Michael Holland Holland and company chairman Michael

great to have you with us in New York let's begin with the IPO that wasn't

and may not be for a long long time.

What's your take away from this whole saga over the last few months?

It started Jonathan before, first of all, thank you for having me on.

It started well before the We Works butting fiasco. Zoom and

Slack have been crucified in the market recently. These are two companies that

came out of the private equity venture capital had traded it

historically crazy numbers relative to their sales which had been growing rapidly but as we saw with

Uber I think may have been the genesis of some of this

Sherman Drang because people were projecting the growth in revenues to be something that would somehow relate to growth in

...